Letters

Food Insecurity and the Dangers of Infant Formula Dilution

The FDA approved concizumab-mtci (Alhemo; Novo Nordisk) for hemophilia A/B without inhibitors, offering once-daily subcutaneous prophylaxis that significantly reduces bleeding rates.

ACIP changes prompt concern as pediatricians prepare for fall vaccine season

Demystifying Infant Formula

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

Larazotide safe, could improve MISC symptoms as adjuvant therapy

Joshua Fitch, Senior Editor

Study: Potty training challenges common, with anxiety and setbacks affecting many families

“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD.

FDA approves concizumab-mtci for hemophilia A/B without inhibitors in patients 12 years and older

Many families face common potty training challenges, including anxiety and setbacks, highlighting the need for patience and personalized strategies.

Related Content

Food Insecurity and the Dangers of Infant Formula Dilution

The FDA approved concizumab-mtci (Alhemo; Novo Nordisk) for hemophilia A/B without inhibitors, offering once-daily subcutaneous prophylaxis that significantly reduces bleeding rates.

ACIP changes prompt concern as pediatricians prepare for fall vaccine season

Demystifying Infant Formula

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

Larazotide safe, could improve MISC symptoms as adjuvant therapy

Joshua Fitch, Senior Editor

Study: Potty training challenges common, with anxiety and setbacks affecting many families

“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD.